Related Experiment Video
Updated: Jul 10, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
[Association between hormone receptors and response to neoadjuvant anthracycline-based chemotherapy in breast cancer
Yan Wei1, Jin-feng Li, Tian-feng Wang
1Breast Center, Department of Pathology, Peking University School of Oncology, Beijing 100036, China.
Objective:
To investigate the associations between the hormone receptors, Ki67 expression and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients.
Methods:
One hundred sixty-eight primary breast cancer patients received anthracycline-based neoadjuvant chemotherapy. The expression of estrogen receptor (ER), progesterone receptor (PR), and Ki67 were determined by immunohistochemistry assay in core-needle biopsy specimens prior to the chemotherapy, and pathologic response was assessed by Miller & Payne grade (G1 to G5).
Results:
40% (67/168) of the patients had a good pathologic response, defined as complete pathologic response (pCR or G5) and minimal residual disease (G4). Among the patients, 20% (33/168) had a complete pathologic response (G5). ER or PR status was significantly associated with pathological response. Patients with PR-negative tumors had a higher pathological response rate or pCR than those with PR-positive tumors (17/67 vs 45/90, P=0.002; 6/67 vs 25/90, P=0.003, respectively), whereas patients with ER-negative tumors had a higher pathological response rate than those with ER-positive tumors. Moreover, Patients with both ER- and PR-negative tumors exhibited a remarkable pathological response as compared with those with any single factor (36/17 vs 26/86, P=0.009). No association between Ki67 expression and pathological was found in this cohort of patients. There was a linear correlation between the expression of Ki67, ER or PR status and pathologic response.
Conclusion:
There is a significant association between the hormone receptors and pathological response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients, and patients with PR-negative tumors are more likely to respond to chemotherapy.
Related Concept Videos
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle
